S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Cross‑trial comparisons and regulatory concerns
Panel cautions against cross‑trial efficacy claims and notes FDA concerns about geographic enrollment and sequencing.
Play episode from 25:47
Transcript
